Jun 14, 2019 - These big pharma stocks all have a Zacks Rank #2 or better.
Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Jun 13, 2019 - Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Jun 11, 2019 - Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Jun 11, 2019 - Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Jun 07, 2019 - The index enjoyed a week of strong gains after the Fed Chair indicated that a near-term rate cut was increasingly likely.